Twitter updates
Donanemab Label Revised: New Dosing Schedule Approved for Early Alzheimer’s Treatment
The FDA approved updated dosing for donanemab in early Alzheimer disease, reducing ARIA-E risk by 41% without compromising efficacy.
The Weekly Dose: Clinical Updates on Cancer Detection, Cognitive Screening, CVD Prevention, Atopic Dermatitis Treatment
Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.
GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns
GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.
The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment
Clinical insights on cannabis and dementia, hormonal contraceptives and postpartum depression, the FDA-approved blood test for Alzheimer disease, more.
New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies
New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.
Body Fat Percentage Outperforms BMI in Predicting Mortality Risk in Young Adults: New Findings
Body fat percentage and waist circumference were both significantly associated with 15-year all-cause mortality while BMI had no significant association.
